Please login to the form below

Not currently logged in
Email:
Password:

Brilique

This page shows the latest Brilique news and features for those working in and with pharma, biotech and healthcare.

NICE backs expanded use of Brilique in final guidance

NICE backs expanded use of Brilique in final guidance

NICE backs expanded use of Brilique in final guidance. AZ’ s maintenance therapy recommended for long-term use, post-heart attack. ... Brilique brought in sales of $395m in the first half of the year and has a 2023 target of $3.5bn.

Latest news

More from news
Approximately 5 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • The evolution of IQWiG in Germany’s drug pricing policy The evolution of IQWiG in Germany’s drug pricing policy

    This includes MSD's hepatitis C drug Victrelis and AstraZeneca's blood clotting drug Brilique. ... With Brilique, IQWiG wanted to split the patient population into four different sub-populations, from which only one received a label of additional benefit.

  • Drug pricing in Ireland Drug pricing in Ireland

    It said that up to 10 new medicines that had proved cost effective through HTA – including Brilique, Gileyna, Sycrest, Incivo and Victrelis – were still not being reimbursed.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • AZ names Brilique lead in Spain AZ names Brilique lead in Spain

    AZ names Brilique lead in Spain. Rodrigo Gribble is promoted to director of acute hospital care unit. ... Gribble has been with AstraZeneca in Spain since 2010, joining as regional sales manager and then as brand manager for Brilique.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics